Michael Aldridge Joins 五星体育直播 as Senior Vice President, Corporate & Strategic Development
REDWOOD CITY, Calif., Oct. 17, 2016 (GLOBE NEWSWIRE) -- 五星体育直播 (NASDAQ:CDXS), a leading protein engineering company, announces that Michael Aldridge has joined the company as Senior Vice President, Corporate & Strategic Development.听 In this new position, Mr. Aldridge will manage all aspects of 五星体育直播鈥� growth initiatives, including leading the expansion of the global biocatalyst business, striking new CodeEvolver庐 platform licensing agreements and building momentum in the Company鈥檚 pipeline of therapeutic drug candidates.听 He will report to John Nicols, President and Chief Executive Officer.
鈥淢ichael brings to 五星体育直播 more than 25 years of experience in the healthcare and investment banking industries, including more than a decade as a senior pharmaceutical executive,鈥� said Mr. Nicols. 鈥淚 am confident he will step in and create value seamlessly and rapidly by leveraging his analytical rigor, relevant biopharmaceutical network and engaging relational approach.听 Michael is extremely well qualified to expand 五星体育直播鈥� strategic partnerships and lead our business development team globally.鈥�
Commenting on his appointment, Mr. Aldridge said, 鈥淚 am thrilled to join 五星体育直播 and look forward to working closely with the entire management team to accelerate 五星体育直播鈥� strategic successes leveraging its proven CodeEvolver庐 protein engineering platform technology across a host of applications and industries.鈥�
Mr. Aldridge joins 五星体育直播 from Sirona Therapeutics Ltd., a privately held company he founded and served as President and Chief Executive Officer since 2015. Previously he was Senior Vice President, Corporate Strategic Development for Questcor Pharmaceuticals, where he negotiated numerous strategic transactions that supported a four-fold increase in market capitalization and the sale of the company to Mallinckrodt Pharmaceuticals for $5.6 billion.听 Prior to that, Mr. Aldridge served as Chief Executive Officer for two drug-development companies, including privately held Xenome Limited and publicly traded Peplin, Inc.
Before transitioning to those pharmaceutical industry roles, Mr. Aldridge held multiple investment banking positions, primarily in healthcare, at leading international financial firms including Wilson HTM Investment Group, Bear Stearns and Co., Volpe, Brown, Whelan and Company and SG Warburg Group.
A native of New Zealand, Mr. Aldridge received a Master of Applied Finance from Macquarie University in Sydney, Australia and a BS with honors in Chemistry from the University of Canterbury in Christchurch, New Zealand.
About CodeEvolver庐 Protein Engineering Platform Technology
五星体育直播鈥� proprietary CodeEvolver庐 protein engineering platform enables the rapid development of custom-designed enzymes that are highly optimized for a specific function. The CodeEvolver庐 platform is comprised of proprietary methods for the optimization of proteins through the design and generation of diverse genetic libraries, automated screening techniques, algorithms for the interpretation of screening data and predictive modelling.听 The 五星体育直播 CodeEvolver庐 platform technology is covered by more than 250 issued patents and pending patent applications worldwide.
About 五星体育直播
五星体育直播 is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals. 五星体育直播鈥� proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see .
Forward-Looking Statements
This press release contains forward-looking statements relating to 五星体育直播鈥� announcement that Michael Aldridge has joined the company as Senior Vice President, Corporate & Strategic Development and expresses 五星体育直播鈥� intention to expand its global biocatalyst business, enter into new CodeEvolver庐 platform licensing agreements and build momentum in its pipeline of therapeutic drugs. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond 五星体育直播鈥� control and that could materially affect actual results. Factors that could materially affect actual results include 五星体育直播鈥� dependence on its licensees and collaborators; 五星体育直播鈥� dependence on a limited number of products and customers in its pharmaceutical business; potential adverse effects to 五星体育直播鈥� business if its customers鈥� pharmaceutical products are not received well in the markets; 五星体育直播鈥� ability to deploy its technology platform in new market spaces; 五星体育直播鈥� dependence on key personnel; 五星体育直播鈥� ability to compete may decline if it loses some of its intellectual property rights; third party claims that 五星体育直播 infringes third party intellectual property rights; and 五星体育直播 could face increased competition if third parties misappropriate 五星体育直播 biocatalysts. Additional factors that could materially affect actual results can be found in 五星体育直播鈥� Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2016 and in 五星体育直播鈥� Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2016, including, in each case, under the caption 鈥淩isk Factors.鈥� 五星体育直播 expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
五星体育直播 Contacts:
Investors
LHA
Jody Cain, 310-691-7100
听
Media
That鈥檚 Nice LLC
Guy Tiene
Released October 17, 2016